4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000018
PRESIDENT AND CFO sold 8,000 shares at an average $71.92 ($575,375)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-06-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 104,720 | D: show line 1 in the form |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-06-18 | Sale 10b5-1 | −7,652 | $71.89 | $550,125 | 97,068 | D: show line 2 in the form |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-06-18 | Sale 10b5-1 | −348 | $72.56 | $25,249 | 96,720 | D: show line 3 in the form |
| Open-market sales · 8,000 sh · avg $71.92 · $575,375 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-06-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 344,827 | D: show line 4 in the form |
Loading xslF345X05/wk-form4_1718929843.xml…